Primary Progressive Aphasia (Logopenic Variant) vs Alzheimer's Disease: tau-total (CSF)


Back to the Top

A large number of studies over the past 20 years have quantified tau protein in the cerebrospinal fluid of people with Alzheimer’s disease, finding that levels of tau in AD patients are more than double those of control subjects. Meta-analysis did not show a diffrence in the levels of tau in the cerebrospinal fluid of people with logopenic variant primary progressive aphasia and people with Alzheimer's disease. However, a paucity of data limited the meta-analysis, with only two eligible studies and a small number of individuals with lvPPA.

Loading data...

How to interpret a forest plot: Each individual effect size (ES) is a ratio of the mean biomarker level in one condition over the mean level in another condition. An ES equal to 1 means that the two conditions had identical mean values. An ES > 1 indicates higher levels in the first condition, whereas an ES < 1 indicates lower levels in the first condition. The overall ES, indicated by a black diamond, is a weighted average of the individual effect sizes. The weight of each data point was determined by the inverse of the variance and is reflected in the size of each square. The width of the overall ES diamond is determined by the 95 percent confidence interval. Data out of range of the scale, including ES and confidence intervals, are indicated by an arrowhead at the edge of the plot, when applicable. 

Version 3.0, July 2021.